
Werewolf Therapeutics (HOWL) Stock Forecast & Price Target
Werewolf Therapeutics (HOWL) Analyst Ratings
Bulls say
Werewolf Therapeutics Inc. is making significant strides in the biopharmaceutical sector with its innovative PREDATOR platform, focused on developing conditionally activated molecules specifically for cancer treatment, which has shown encouraging clinical activities across multiple programs. The company’s lead candidates, WTX-124 and WTX-330, are demonstrating favorable safety profiles with manageable adverse effects and promising anti-tumor activity, suggesting that the platform effectively expands the therapeutic window while mitigating systemic toxicity. With ongoing developments and a potential expansion into other therapeutic areas beyond oncology, Werewolf’s robust portfolio positions it favorably in the evolving landscape of immunotherapy.
Bears say
Werewolf Therapeutics posted a significant net loss of $20.4 million, or $0.46 per share, for the fourth quarter of 2024, representing an increase from a $12.0 million loss in the same quarter the previous year, which raises concerns about its financial sustainability. The company faces risks related to potential clinical or regulatory setbacks linked to WTX-124, as well as challenges in meeting revenue estimates if the product receives approval. Additionally, uncertainties regarding WTX-124's safety, efficacy, and competitive positioning in a landscape of existing and emerging therapies further contribute to a cautious outlook on the stock.
This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Werewolf Therapeutics (HOWL) Analyst Forecast & Price Prediction
Start investing in Werewolf Therapeutics (HOWL)
Order type
Buy in
Order amount
Est. shares
0 shares